The STING pathway targeting technologies market is projected to grow at an annualized rate of ~25%,
Many small / macro molecule-based STING pathway modulators are currently being evaluated as monotherapies as well as in combination with other drugs. The pipeline features candidates targeting different therapeutic areas and designed for administration through a variety of routes; majority of such therapeutics are being developed as third-line and second-line treatments
